Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Neurologia i Neurochirurgia Polska
MENU
Shortcuts Submit an article Guide for Authors Special collections Ahead Of Print Reviewers 2023

open access

Vol 57, No 2 (2023)
Research Paper
Submitted: 2022-08-22
Accepted: 2022-12-05
Published online: 2022-12-20
View PDF Download PDF file View HTML
Get Citation

Functional improvement of young children with cerebral palsy treated with integrated/intensive rehabilitation and botulinum toxin injections

Marcin Bonikowski1, Magdalena Chrościnska-Krawczyk2, Weronika Pyrzanowska1
DOI: 10.5603/PJNNS.a2022.0081
·
Pubmed: 36537370
·
Neurol Neurochir Pol 2023;57(2):183-188.
Affiliations
  1. Mazovian Neuropsychiatry Centre, Neuro Rehabilitation Department, Movement Analysis Laboratory, Zagorze, Poland
  2. Department of Child Neurology, University Children’s Hospital, Lublin, Poland

open access

Vol 57, No 2 (2023)
Research papers
Submitted: 2022-08-22
Accepted: 2022-12-05
Published online: 2022-12-20

Abstract

Introduction. Patients with cerebral palsy (CP) present mobility limitations altering their activity and participation in social life. The aim of this study was to assess changes in Gross Motor Function Classification System (GMFCS) and Functional Mobility Scale (FMS) in children with CP who received repeated BoNT-A injections within a rehabilitation treatment over a five-year follow-up period.

Material and methods. This retrospective, observational study included 200 consecutive children with bilateral CP (GMFCS I–IV). Annual assessments of the five-year follow-up period were analysed.

Results. The mean age of the patients at the beginning was 32.23 months (± 6.96). The GMFCS level improved in 67 (33.5%) (p < 0.001) and worsened in four (2%) children. In children with GMFCS III and IV levels, improvement was observed in 50% and 40%, respectively. FMS 5 and 50 metres improved in 54% and 52.5% of children respectively.

Conclusions. Our study showed a significant, positive effect of integrated treatment on functional mobility in patients with CP.

Abstract

Introduction. Patients with cerebral palsy (CP) present mobility limitations altering their activity and participation in social life. The aim of this study was to assess changes in Gross Motor Function Classification System (GMFCS) and Functional Mobility Scale (FMS) in children with CP who received repeated BoNT-A injections within a rehabilitation treatment over a five-year follow-up period.

Material and methods. This retrospective, observational study included 200 consecutive children with bilateral CP (GMFCS I–IV). Annual assessments of the five-year follow-up period were analysed.

Results. The mean age of the patients at the beginning was 32.23 months (± 6.96). The GMFCS level improved in 67 (33.5%) (p < 0.001) and worsened in four (2%) children. In children with GMFCS III and IV levels, improvement was observed in 50% and 40%, respectively. FMS 5 and 50 metres improved in 54% and 52.5% of children respectively.

Conclusions. Our study showed a significant, positive effect of integrated treatment on functional mobility in patients with CP.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

cerebral palsy, integrated rehabilitation, botulinum toxin-A, mobility, gross motor function

About this article
Title

Functional improvement of young children with cerebral palsy treated with integrated/intensive rehabilitation and botulinum toxin injections

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 57, No 2 (2023)

Article type

Research Paper

Pages

183-188

Published online

2022-12-20

Page views

2299

Article views/downloads

626

DOI

10.5603/PJNNS.a2022.0081

Pubmed

36537370

Bibliographic record

Neurol Neurochir Pol 2023;57(2):183-188.

Keywords

cerebral palsy
integrated rehabilitation
botulinum toxin-A
mobility
gross motor function

Authors

Marcin Bonikowski
Magdalena Chrościnska-Krawczyk
Weronika Pyrzanowska

References (33)
  1. Bax M, Goldstein M, Rosenbaum P, et al. Executive Committee for the Definition of Cerebral Palsy. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005; 47(8): 571–576.
    CrossRefPubMed
  2. Oskoui M, Coutinho F, Dykeman J, et al. An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. [Erratum in: Dev Med Child Neurol. 2016 Mar;58(3):316. PMID: 23346889]. Dev Med Child Neurol. 2013; 55(6): 509–519.
    CrossRefPubMed
  3. Narayanan UG. Management of children with ambulatory cerebral palsy: an evidence-based review. J Pediatr Orthop. 2012; 32 Suppl 2: S172–S181.
    CrossRefPubMed
  4. Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997; 39(4): 214–223.
    CrossRefPubMed
  5. Palisano RJ, Rosenbaum P, Bartlett D, et al. Content validity of the expanded and revised Gross Motor Function Classification System. Dev Med Child Neurol. 2008; 50(10): 744–750.
    CrossRefPubMed
  6. Voorman JM, Dallmeijer AJ, Schuengel C, et al. Activities and participation of 9- to 13-year-old children with cerebral palsy. Clin Rehabil. 2006; 20(11): 937–948.
    CrossRefPubMed
  7. Wood E, Rosenbaum P. The gross motor function classification system for cerebral palsy: a study of reliability and stability over time. Dev Med Child Neurol. 2000; 42(5): 292–296.
    CrossRefPubMed
  8. Rosenbaum PL, Walter SD, Hanna SE, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. JAMA. 2002; 288(11): 1357–1363.
    CrossRefPubMed
  9. Hanna SE, Rosenbaum PL, Bartlett DJ, et al. Stability and decline in gross motor function among children and youth with cerebral palsy aged 2 to 21 years. Dev Med Child Neurol. 2009; 51(4): 295–302.
    CrossRefPubMed
  10. Graham HK, Harvey A, Rodda J, et al. The Functional Mobility Scale (FMS). J Pediatr Orthop. 2004; 24(5): 514–520.
    CrossRefPubMed
  11. Harvey A, Rosenbaum P, Hanna S, et al. Longitudinal changes in mobility following single-event multilevel surgery in ambulatory children with cerebral palsy. J Rehabil Med. 2012; 44(2): 137–143.
    CrossRefPubMed
  12. Opheim A, Jahnsen R, Olsson E, et al. Walking function, pain, and fatigue in adults with cerebral palsy: a 7-year follow-up study. Dev Med Child Neurol. 2009; 51(5): 381–388.
    CrossRefPubMed
  13. Bonikowski M, Sławek J. Safety and efficacy of Botulinum toxin type A preparations in cerebral palsy — an evidence-based review. Neurol Neurochir Pol. 2021; 55(2): 158–164.
    CrossRefPubMed
  14. Love SC, Novak I, Kentish M, et al. Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol. 2010; 17 Suppl 2: 9–37.
    CrossRefPubMed
  15. Yana M, Tutuola F, Westwater-Wood S, et al. The efficacy of botulinum toxin A lower limb injections in addition to physiotherapy approaches in children with cerebral palsy: A systematic review. NeuroRehabilitation. 2019; 44(2): 175–189.
    CrossRefPubMed
  16. Rosenbaum P, Stewart D. The World Health Organization International Classification of Functioning, Disability, and Health: a model to guide clinical thinking, practice and research in the field of cerebral palsy. Semin Pediatr Neurol. 2004; 11(1): 5–10.
    CrossRefPubMed
  17. Fisher A, Hammersley ML, Jones RA, et al. Goal setting for weight-related behavior change in children: An exploratory study. Nutr Health. 2018; 24(2): 67–74.
    CrossRefPubMed
  18. Molenaers G, Fagard K, Van Campenhout A, et al. Botulinum toxin A treatment of the lower extremities in children with cerebral palsy. J Child Orthop. 2013; 7(5): 383–387.
    CrossRefPubMed
  19. Chiarello LA, Palisano RJ, Bartlett DJ, et al. A multivariate model of determinants of motor change for children with cerebral palsy. Phys Ther. 2000; 80(6): 598–614.
    PubMed
  20. Wright FV, Rosenbaum PL, Goldsmith CH, et al. How do changes in body functions and structures, activity, and participation relate in children with cerebral palsy? Dev Med Child Neurol. 2008; 50(4): 283–289.
    CrossRefPubMed
  21. Molenaers G, Van Campenhout A, Fagard K, et al. The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. J Child Orthop. 2010; 4(3): 183–195.
    CrossRefPubMed
  22. Palisano RJ, Tieman B, Walter SD, et al. Effect of environmental setting on mobility methods of children with cerebral palsy. Dev Med Child Neurol. 2003; 45(2): 113–120.
    PubMed
  23. Palisano RJ, Avery L, Gorter JW, et al. Stability of the Gross Motor Function Classification System, Manual Ability Classification System, and Communication Function Classification System. Dev Med Child Neurol. 2018; 60(10): 1026–1032.
    CrossRefPubMed
  24. Palisano RJ, Cameron D, Rosenbaum PL, et al. Stability of the gross motor function classification system. Dev Med Child Neurol. 2006; 48(6): 424–428.
    CrossRefPubMed
  25. Alriksson-Schmidt A, Nordmark E, Czuba T, et al. Stability of the Gross Motor Function Classification System in children and adolescents with cerebral palsy: a retrospective cohort registry study. Dev Med Child Neurol. 2017; 59(6): 641–646.
    CrossRefPubMed
  26. Nylén E, Grooten WJA. The Stability of the Gross Motor Function Classification System in Children with Cerebral Palsy Living in Stockholm and Factors Associated with Change. Phys Occup Ther Pediatr. 2021; 41(2): 138–149.
    CrossRefPubMed
  27. Cobanoglu M, Cullu E, Omurlu I. The effect of hip reconstruction on gross motor function levels in children with cerebral palsy. Acta Orthop Traumatol Turc. 2018; 52(1): 44–48.
    CrossRefPubMed
  28. Ailon T, Beauchamp R, Miller S, et al. Long-term outcome after selective dorsal rhizotomy in children with spastic cerebral palsy. Childs Nerv Syst. 2015; 31(3): 415–423.
    CrossRefPubMed
  29. Dursun N, Akyuz M, Gokbel T, et al. GMFCS level improvement in children with cerebral palsy treated with repeat botulinum toxin injections and intensive rehabilitation: A retrospective study. J Pediatr Rehabil Med. 2022; 15(1): 107–112.
    CrossRefPubMed
  30. Strobl W, Theologis T, Brunner R, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins (Basel). 2015; 7(5): 1629–1648.
    CrossRefPubMed
  31. Gage JR, Novacheck TF. An update on the treatment of gait problems in cerebral palsy. J Pediatr Orthop B. 2001; 10(4): 265–274.
    PubMed
  32. Trabacca A, Vespino T, Di Liddo A, et al. Multidisciplinary rehabilitation for patients with cerebral palsy: improving long-term care. J Multidiscip Healthc. 2016; 9: 455–462.
    CrossRefPubMed
  33. Richards T, Coulter A, Wicks P. Time to deliver patient centred care. BMJ. 2015; 350: h530.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl